Global Next-Generation Sequencing (NGS) Market Size By Type (Sequencing by Synthesis, Ion Semiconductor Sequencing), By Application (Academic Institutes & Research Centers, Hospitals & Clinics), By Re...

The Global Next-Generation Sequencing (NGS) Market was valued at USD 12.1 billion in 2023 and is projected to reach USD 32.7 billion by 2031, growing at a CAGR of 13.4% during the forecast period from 2023 to 2031. The market is witnessing robust growth due to the increasing demand for precision medicine, advancements in sequencing technologies, and the declining cost of sequencing. NGS has revolutionized genomic research and diagnostics by enabling high-throughput analysis of genetic material with exceptional accuracy and speed. The growing applications of NGS in clinical diagnostics, oncology, reproductive health, and personalized medicine are key contributors to its market expansion.

Drivers:

1. Rising Demand for Precision Medicine:

Precision medicine aims to customize healthcare based on individual genetic profiles. NGS plays a pivotal role by offering deep insights into the genetic basis of diseases, thus enabling targeted therapies. The rapid rise in chronic diseases like cancer has further propelled the use of NGS for personalized treatment strategies.

2. Technological Advancements in Sequencing Platforms:

Innovations in NGS technologies, including long-read sequencing, single-cell sequencing, and nanopore technologies, are enhancing the scope and scalability of sequencing projects. These advances are improving accuracy, reducing turnaround time, and lowering sequencing costs.

3. Expanding Applications in Clinical Diagnostics:

NGS is becoming a core diagnostic tool for various conditions, especially in oncology, where it assists in tumor profiling, companion diagnostics, and tracking treatment responses. Its application in non-invasive prenatal testing (NIPT) and rare disease diagnosis is also gaining traction.

Restraints:

1. High Capital Investment and Infrastructure Needs:

The initial cost for setting up NGS infrastructure—including instruments, reagents, and data analysis tools—is substantial. Additionally, maintaining and calibrating these systems requires ongoing investment, which may hinder adoption in low-resource settings.

2. Data Interpretation and Regulatory Challenges:

NGS generates massive volumes of complex data, which necessitates advanced bioinformatics tools and expert interpretation. Moreover, evolving regulatory frameworks and ethical concerns around data privacy and genetic testing can pose hurdles to market growth.

Opportunity:

1. Growth in Liquid Biopsy and Companion Diagnostics:

The increasing focus on early cancer detection and minimally invasive procedures is driving the adoption of liquid biopsy technologies powered by NGS. Furthermore, the surge in demand for companion diagnostics to support targeted therapies offers significant growth potential for NGS developers.

Market by System Type Insights:

By system type, the Sequencing by Synthesis (SBS) segment accounted for the largest revenue share in 2023. SBS is widely adopted due to its high throughput and accuracy, making it suitable for large-scale genome, exome, and transcriptome studies. The Nanopore Sequencing segment, however, is expected to grow at the highest CAGR during the forecast period due to its portability, real-time data output, and ability to read long DNA or RNA fragments.

Market by End-use Insights:

The Clinical Diagnostics segment dominated the market in 2023, contributing more than 45% of the global revenue. NGS has become indispensable in clinical settings for genetic screening, oncology diagnostics, and infectious disease testing. The Research Institutions segment also holds a significant share, driven by academic and government initiatives to fund genomic research projects.

Market by Regional Insights:

North America led the global NGS market in 2023, supported by a strong presence of leading genomics companies, robust research infrastructure, and favorable reimbursement policies. Asia-Pacific is projected to exhibit the fastest growth during the forecast period, owing to rising healthcare expenditures, increasing awareness of genomics, and expanding R&D capabilities in countries like China, Japan, and India.

Competitive Scenario:

Key players in the Global Next-Generation Sequencing Market include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Oxford Nanopore Technologies, Agilent Technologies, QIAGEN, BGI Genomics, PerkinElmer, Inc., F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories, Inc. These companies are heavily investing in R&D, forming strategic collaborations, and launching advanced sequencing solutions to maintain their market leadership.

Scope of Work – Global Next-Generation Sequencing (NGS) Market

Report Metric Details

Market Size (2023) USD 12.1 billion

Projected Market Size (2031) USD 32.7 billion

CAGR (2023–2031) 13.4%

Key Segments by System Type Sequencing by Synthesis, Nanopore Sequencing, Pyrosequencing

Key Segments by End-Use Clinical Diagnostics, Academic & Research Institutions, Pharmaceutical Companies

Leading Region North America

Key Players Illumina, Thermo Fisher Scientific, Oxford Nanopore, BGI Genomics, QIAGEN

Growth Drivers Precision medicine, oncology diagnostics, cost decline in sequencing

Opportunities Liquid biopsy growth, rise in personalized medicine, companion diagnostics

Key Market Developments:

2023: Illumina launched its NextSeq 2000 platform upgrade with improved throughput and reduced per-sample cost, targeting mid-scale clinical labs and research centers.

2024: Oxford Nanopore Technologies expanded its presence in Asia-Pacific through strategic partnerships with genomic institutes in India and China.

2025: Thermo Fisher Scientific acquired a bioinformatics firm to enhance its data analytics capabilities for clinical-grade NGS applications.

FAQs:

1. What is the current market size of the Global Next-Generation Sequencing (NGS) Market?

The market was valued at USD 12.1 billion in 2023.

2. What is the major growth driver of the Global Next-Generation Sequencing (NGS) Market?

The major growth driver is the rising demand for precision medicine and the expanding application of NGS in clinical diagnostics.

3. Which is the largest region during the forecast period in the Global Next-Generation Sequencing (NGS) Market?

North America is the largest region, driven by high adoption and advanced genomic infrastructure.

4. Which segment accounted for the largest market share in the Global Next-Generation Sequencing (NGS) Market?

The Clinical Diagnostics segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Next-Generation Sequencing (NGS) Market?

Key players include Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, BGI Genomics, and QIAGEN.